Get the Stockscreener App
1.78
6.81%
-0.13
Pre-market:
1.87
0.09
+5.06%
Cabaletta Bio Inc stock is traded at $1.78, with a volume of 813.49K.
It is down -6.81% in the last 24 hours and down -34.07% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$1.91
Open:
$1.93
24h Volume:
813.49K
Relative Volume:
0.58
Market Cap:
$87.00M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.0723
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
-5.32%
1M Performance:
-34.07%
6M Performance:
-56.69%
1Y Performance:
-91.21%
1-Day Range:
$1.78
$2.00
1-Week Range:
$1.68
$2.01
52-Week Range:
$1.66
$20.24
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.78 | 87.00M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World
Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN
Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com Australia
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference - TradingView
Can Cabaletta Bio's Conference Appearance Signal New Autoimmune Treatment Progress? - StockTitan
Is Now The Time To Buy Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register
Cabaletta Bio Reveals Promising Clinical Data for Autoimmune Therapy - MSN
HC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc (CABA) Stock: Navigating Drops and Gains - The InvestChronicle
Cabaletta Bio (NASDAQ:CABA) Given “Buy” Rating at HC Wainwright - Defense World
Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $22.71 - MarketBeat
Shopify Stock Forecast: Can SHOP Hit $175 in 2025? - The Globe and Mail
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Earnings To Watch: Herbalife (HLF) Reports Q4 Results Tomorrow - The Globe and Mail
Breakthrough Clinical Results: Rese-cel Treatment Achieves Remission in Lupus Patients, Shows Promise Across Autoimmune Disorders - StockTitan
What To Expect From Fiverr’s (FVRR) Q4 Earnings - The Globe and Mail
UPDATECabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings - Business Upturn
Cabaletta Bio’s rese-cel shows efficacy in clinical studies - TipRanks
Cabaletta Bio Unveils Promising Clinical Data in RESET Trials - TipRanks
Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings - Marketscreener.com
Revolutionary Autoimmune Treatment Success: Patients Achieve Complete Remission, Stop All Medications - StockTitan
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings | Dow Theory Letters - Financial Content
Kyndryl Soars on AI, Cybersecurity Growth—What’s Next? - The Globe and Mail
Tri Pointe Homes (TPH) To Report Earnings Tomorrow: Here Is What To Expect - The Globe and Mail
Cabaletta Bio Advances Autoimmune Therapy, Sets Strategic Goals for 2025 - MSN
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
SG Americas Securities LLC Purchases 8,161 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Guggenheim’s SMID Cap Biotech Conference - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February - The Manila Times
Cabaletta Bio to Present Updated Clinical Data on Rese-cel at 2025 Scientific Conferences - Nasdaq
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February | Dow Theory Letters - Financial Content
Cabaletta Bio Inc (CABA) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Teradata Earnings: What To Look For From TDC - The Globe and Mail
Jennison Associates LLC Cuts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Recent uptick might appease Cabaletta Bio, Inc. (NASDAQ:CABA) institutional owners after losing 89% over the past year - Simply Wall St
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):